Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
about
Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistanceRadiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancerEndothelial Transdifferentiation of Tumor Cells Triggered by the Twist1-Jagged1-KLF4 Axis: Relationship between Cancer Stemness and AngiogenesisReducing Tumour Hypoxia via Oral Administration of Oxygen NanobubblesPhase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.Cytotoxic and antioxidant properties of active principals isolated from water hyacinth against four cancer cells linesNuclear expression of dynamin-related protein 1 in lung adenocarcinomas.Role of nitric oxide in Salmonella typhimurium-mediated cancer cell killingIn Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA.Exosomal Proteome Profiling: A Potential Multi-Marker Cellular Phenotyping Tool to Characterize Hypoxia-Induced Radiation Resistance in Breast Cancer.HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein.Proteomic screening of anaerobically regulated promoters from Salmonella and its antitumor applications.Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3.Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancerHypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotypeReal-time determination of intracellular oxygen in bacteria using a genetically encoded FRET-based biosensorHIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional functionHIF-1α up-regulates NDRG1 expression through binding to NDRG1 promoter, leading to proliferation of lung cancer A549 cells.Quenching enhancement of the singlet excited state of pheophorbide-a by DNA in the presence of the quinone carboquoneA hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy.Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy.F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapyContribution of patient related differences to multidrug resistance in rheumatoid arthritis.Transcriptionally targeted gene therapy to detect and treat cancer.Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells.Tumor hypoxia: a target for selective cancer therapy.Krüppel-like factor 8 contributes to hypoxia-induced MDR in gastric cancer cells.Development of hypoxia enhanced 111In-labeled Bombesin conjugates: design, synthesis, and in vitro evaluation in PC-3 human prostate cancer.Promoter G-quadruplex sequences are targets for base oxidation and strand cleavage during hypoxia-induced transcriptionDelivery systems and molecular targets of mechanism-based therapies for GBM.Effect of Heat-Inactivated Clostridium sporogenes and Its Conditioned Media on 3-Dimensional Colorectal Cancer Cell ModelsSENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy.Epigenetics, TET proteins, and hypoxia in epithelial-mesenchymal transition and tumorigenesisImpact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantroneRedox homeostasis protects mitochondria through accelerating ROS conversion to enhance hypoxia resistance in cancer cells.Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive elementEnhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response.
P2860
Q24290673-467F26C4-2C1E-4B21-8972-3F6B6279B5CAQ24616197-9EA41D45-81FB-4797-ABD4-B5CEE91F8485Q26773015-5CF80767-488A-41D4-B528-05B529FAC911Q28468506-E7258EA3-B520-46FF-9BE2-B1C43BBEEBB2Q30408170-A09138B6-E41F-485C-A8F3-E23064B679F2Q30860272-F55BD20F-F00A-4127-A82E-39E8CB8D65A2Q33467361-449B44B4-0FD3-417C-A4EA-FB21B336D98EQ33557865-C2B3A2B4-2327-4929-AB46-40B9B49E9958Q33568871-82C2CF8F-3217-454C-863B-2E4A12D61326Q33644570-E0EDD4AB-B291-4DA1-AF59-70D5597843CCQ33717131-AAE9E2FC-CBC5-4668-BE03-E069316D95C9Q33865605-8A49B26E-E295-4A4A-9B0E-FD8D886CBE0EQ33945427-951F243D-A32D-4E7A-B4DE-8147FF035819Q33994365-37C3E34A-8443-45CA-A9B4-DB9FBB0C2690Q34068218-28FB3D45-276A-4565-9C36-6279303F56F2Q34206656-C8D58493-D724-442D-91E3-83C1D98FB06FQ34586733-F0ED2004-D56B-4F9A-92CF-956733B1A31EQ34633777-76A1A5B5-A063-49FE-B557-042BB6FF4086Q34758431-FF7EF131-382A-422F-9A59-4A417DD8B5D4Q34779805-F46D5755-2DD8-4F83-BB46-8414D44C96D8Q34819107-35A13EDE-DDFF-4202-93CF-6E9367388238Q35116993-D27ABDDF-832E-45E6-BE50-009F520A1296Q35551965-1047C842-CD80-4F71-A648-B8EFC53F7214Q35558678-7EF14096-EFD9-462F-BA70-155F199E9CFCQ35589210-8876C820-C2AE-49FA-9F8D-B5151354EE9AQ35602696-EC3EAFF7-7A9B-414A-A575-D24D7BABA73BQ35713698-27B6386D-7575-4B45-81F3-4D7C34D7EFF9Q35846757-779E8722-00A5-413C-B8F2-8C8B302A7ACAQ36040836-7738EA17-8E57-41F4-9E91-702DEDA2A396Q36107160-9AE8841B-1388-4E1C-9211-21B71BF8C0A0Q36216216-046E68BA-748F-486C-B359-5680A8A01B02Q36262399-F7EF0CB2-E9F1-430B-8FBF-B9B40C9F5ED5Q36271313-9A36219E-C149-4FFA-99BD-2E68C14C059EQ36573115-AD5EC750-0B75-4A1D-81C9-9E6EF0896A40Q36573248-A08FAE91-969A-44C4-8DDB-D8CACB4C530EQ36666779-02B70A52-C732-4510-8C65-6DF7EA156FC0Q36706902-E7FABB28-FE32-45A8-821E-2C5A5AEC7D80Q36714784-CE138AB8-BAB0-46D8-B8F6-0A71F786E869Q36876347-70DD138C-44C4-40F6-B88B-4458703806D5Q36980048-885A953D-30EC-49B4-8DE7-FF6BFDBF3FB9
P2860
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
@ast
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
@en
type
label
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
@ast
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
@en
prefLabel
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
@ast
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
@en
P1476
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
@en
P2093
P304
P356
10.1016/S1357-4310(00)01677-4
P577
2000-04-01T00:00:00Z